These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7347126)

  • 1. The effect of I.V. glucagon administration on selected metabolic parameters in patients with type IIa, IIb and IV primary hyperlipoproteinaemia.
    Andĕl M; Brodan V; Kucerová L; Brodanová M
    Acta Univ Carol Med (Praha); 1980; 26(5-6):271-92. PubMed ID: 7347126
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cholesterol and triglyceride plasma levels in patients with primary hyperlipoproteinemia. Decline after short-term i.v. glucagon administration].
    Andĕl M; Brodan V; Kucerová L; Grafnetter D; Kuhn E; Veselková A
    Cas Lek Cesk; 1980 May; 119(22):616-21. PubMed ID: 7427980
    [No Abstract]   [Full Text] [Related]  

  • 3. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J; Martorell J
    Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-mediated immune response in patients with type IIa, type IIb and type IV primary hyperlipoproteinaemia.
    Antonaci S; Jirillo E; Garofalo AR; Polignano A; Resta F; Pugliese P; Capurso A; Bonomo L
    Cytobios; 1988; 54(218-219):181-9. PubMed ID: 3263908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible glucagon-mediated hypocholesterolemic activity of a nicotinic acid derivative (sorbinicate).
    Uccella R; Morenghi R; Agosti C; Saponati G
    Artery; 1983; 11(5):400-12. PubMed ID: 6661043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
    Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparison of the effects of fenofibrate administered in doses of 3 x 100mg and 1 x 250mg per day in patients with type IIA, IIB and IV hyperlipoproteinemias].
    Reiner Z; Salzer B; Kes P
    Acta Med Iugosl; 1988; 42(5):353-62. PubMed ID: 3245481
    [No Abstract]   [Full Text] [Related]  

  • 9. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IIB and IV].
    Chwistecki K; Mrukowicz M; Kopel E
    Przegl Lek; 1984; 41(9):581-6. PubMed ID: 6393227
    [No Abstract]   [Full Text] [Related]  

  • 10. Glucagon and primary hyperlipidemias.
    Jover E; Velasco R; Rodriguez F
    J Med; 1983; 14(5-6):389-94. PubMed ID: 6366105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
    Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of lipanthyl on parameters of lipid metabolism in patients with primary hyperlipoproteinemia].
    Sznajd J; Magdoń M; Idzior B; Konarska R; Malczewska M; Czarnecka H
    Przegl Lek; 1984; 41(2):217-21. PubMed ID: 6377392
    [No Abstract]   [Full Text] [Related]  

  • 13. Oxidative burst and lysosomal enzyme release by polymorphonuclear cells in type IIa, type IIb and type IV primary hyperlipoproteinaemia.
    Ventura MT; Puzziferri I; Tortorella C; Resta F; Capurso A; Antonaci S
    Recenti Prog Med; 1993; 84(7-8):503-10. PubMed ID: 8356303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical pharmacology of DEAE-dextran. Metabolic and secondary effects in long-term treatment].
    Pupita F; Barone A; Oliva S; Gaggi S; Pupita G
    Clin Ter; 1986 Feb; 116(3):171-8. PubMed ID: 2421967
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of the administration of silymarin on serum lipid levels].
    Petronelli A; Roda E; Briganti M; Morselli Labate AM; Barbara L
    Clin Ter; 1981 Dec; 99(5):471-82. PubMed ID: 7333068
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of procetofen on lipoproteins and blood lipids in patients with hyperlipemia].
    Abaurre R; Vega J; Maneschi E; Bernabe H
    Medicina (B Aires); 1980; 40(6 Pt 2):896. PubMed ID: 7219169
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
    Vorberg G; Ziegler WJ
    Arzneimittelforschung; 1980; 30(11b):2068-72. PubMed ID: 7194062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of lipanthyl therapy on hyperlipoproteinemia type II/a, II/b and IV].
    Karádi I; Pados G; Németh-Csóka M; Romics L
    Orv Hetil; 1988 Aug; 129(33):1757-60. PubMed ID: 3174116
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.